Answers are grounded in this paper and cite their sources.
BACKGROUND: Calprotectin is the major cytosolic protein in neutrophil granulocytes. Although asthma is known to cause eosinophilic inflammation, some patients with asthma have non-eosinophilic inflammation, which is characterized by local neutrophilic inflammation. The aim of this study was to assess calprotectin expression levels in a mouse model of asthma, and to observe the relationship of serum calprotectin level and clinical variables in patients with asthma. The levels of calprotectin were determined using enzyme-linked immunosorbent assay, immunoblotting, and immunohistochemical analysis. The serum levels of calprotectin were also assessed in patients with asthma. The relationship between calprotectin and clinicopathological characteristics was determined. CONCLUSION: Our data suggest that calprotectin could potentially be used as a biomarker for asthma.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: